Olumide B. Gbolahan, MBBS, MSc ...

Dr. Olumide Gbolahan

Claim this profile

Emory University Hospital/Winship Cancer Institute

Studies Colorectal Cancer
Studies Liver Cancer
13 reported clinical trials
39 drugs studied

Area of expertise

1Colorectal Cancer
Olumide Gbolahan has run 5 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Liver Cancer
Olumide Gbolahan has run 4 trials for Liver Cancer. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
Emory University Hospital/Winship Cancer Institute
Image of trial facility.
University Of Alabama At Birmingham

Clinical Trials Olumide Gbolahan is currently running

Image of trial facility.

Tucatinib + Trastuzumab + Chemotherapy

for Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Lenvatinib

for Recurrent Liver Cancer Post-Transplant

This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Systemic treatments for HCC have not been studied in patients with recurrent HCC after liver transplantation, so there is no established therapy for these patients. This phase II trial evaluates lenvatinib for this purpose.
Recruiting1 award Phase 2

More about Olumide Gbolahan

Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Olumide Gbolahan has experience with
  • Bevacizumab
  • Trastuzumab
  • Tucatinib
  • Regorafenib
  • Oxaliplatin
  • Fluorouracil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Olumide Gbolahan specialize in?
Is Olumide Gbolahan currently recruiting for clinical trials?
Are there any treatments that Olumide Gbolahan has studied deeply?
What is the best way to schedule an appointment with Olumide Gbolahan?
What is the office address of Olumide Gbolahan?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security